Pulmatrix, Inc. (PULM)
NASDAQ: PULM · Real-Time Price · USD
1.310
-0.010 (-0.76%)
Apr 2, 2026, 4:00 PM EDT - Market closed
Pulmatrix Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
2
Market Cap
4.78M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 7.81M | 508.00K | 6.96% |
| Dec 31, 2023 | 7.30M | 1.23M | 20.21% |
| Dec 31, 2022 | 6.07M | 902.00K | 17.45% |
| Dec 31, 2021 | 5.17M | -7.47M | -59.09% |
| Dec 31, 2020 | 12.63M | 4.72M | 59.72% |
| Dec 31, 2019 | 7.91M | 7.76M | 5,069.93% |
| Dec 31, 2018 | 153.00K | -182.00K | -54.33% |
| Dec 31, 2017 | 335.00K | -500.00K | -59.88% |
| Dec 31, 2016 | 835.00K | -366.00K | -30.47% |
| Dec 31, 2015 | 1.20M | - | - |
| Mar 31, 2015 | - | - | - |
| Dec 31, 2014 | 352.00K | - | - |
| Mar 31, 2014 | - | - | - |
| Mar 31, 2013 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Moolec Science | 7.83M |
| VivoSim Labs | 142.00K |
| AIM ImmunoTech | 88.00K |
| Silo Pharma | 72.10K |
| Aspire Biopharma Holdings | 6.20K |
PULM News
- 9 days ago - Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan - PRNewsWire
- 4 weeks ago - Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities - PRNewsWire
- 5 weeks ago - Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results - PRNewsWire
- 3 months ago - Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives - PRNewsWire
- 6 months ago - Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets - PRNewsWire
- 8 months ago - Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets - PRNewsWire
- 11 months ago - Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets - PRNewsWire
- 11 months ago - PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc. - PULM - Business Wire